US continues sanctions against Iran despite coronavirus ravaging both nations
March 23, 2020Manufacturing and Production, Sales and Marketing Iran, Iran US, US, coronavirus
The Trump administration is not relaxing sanctions on Iran, despite the country having one of the highest death tolls from …
Los Angeles County and California State near lockdown after “safer-at-home” mandate is announced
March 20, 2020Medical Communications Wuhan Coronavirus, china coronavirus, coronavirus
Last night, Los Angeles County, and later California State, announced a mandate to make people work and stay at home …
FDA greenlights Gilead’s Epclusa in hepatitis C patients over six years old
March 20, 2020Medical Communications, Research and Development Epclusa, Gilead, pharma
Gilead’s Epclusa (sofosbuvir and velpatasvir) has been awarded new marketing approval from the FDA in the treatment of hepatitis C …
Top Ten most popular articles on Pharmafile.com this week
March 20, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chinese Coronavirus, Wuhan Coronavirus, china coronavirus, coronavirus
The COVID-19 coronavirus continues to dominate the news: A flu drug has appeared to be effective in treating COVID-19 while …
Drug launches across Europe will be affected by coronavirus
March 20, 2020Medical Communications, Sales and Marketing EU, Europe, coronavirus, pharma
The COVID-19 pandemic will affect European launches of drugs for a host of diseases including HIV, cancer and sickle cell …
New findings on influenza could help improve cancer treatments
March 20, 2020Manufacturing and Production, Medical Communications Cancer, cancer treatments, flu, flu treatments, influenza
A new study into how the body fights influenza could help improve cancer immunotherapies. Researchers at the Fox Chase Cancer …
Japan grants orphan drug designation to Lynparza for BRCA+ unresectable pancreatic cancer
March 19, 2020Research and Development, Sales and Marketing AstraZeneca, Japan, lynparza, pharma
AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …
EMA calls on EU to pool resources together to carry out large scale clinical trials against COVID-19
March 19, 2020Business Services COVID-19, Chinese Coronavirus, Wuhan Coronavirus, coronavirus
The European Medicines Agency (EMA) has called on the European Union to collaborate closely on carrying out clinical trials on …
Japan approves Novartis’ Zolgensma for spinal muscular atrophy in patients under two years old
March 19, 2020Sales and Marketing Japan, Novartis, Zolgensma, pharma, spinal muscular atrophy
Novartis has revealed that its gene therapy Zolgensma (onasemnogene abeparvovec) has secured approval from Japan’s Ministry of Health, Labour and …
COVID-19 can survive in aerosol form and on hard surfaces from hours to days, new study shows
March 19, 2020Business Services COVID-19, Wuhan Coronavirus, china coronavirus, coronavirus
New research shows that the COVID-19 coronavirus is stable for hours to days in aerosols and on surfaces. This study was …
NICE and EMA to review if Ibuprofen and other anti-inflammatories worsen coronavirus
March 19, 2020Business Services British Coronavirus, Wuhan Coronavirus, china coronavirus, coronavirus
The National Institute for Health and Care Excellence (NICE) and the European Medicines Regulatory have both stated that there is …
Global drug spending projected to reach $1.1 trillion by 2024, report argues
March 18, 2020Research and Development, Sales and Marketing IQVIA, pharma, report
Total global spending on medicines is set to break $1.1 trillion by 2024, a new report released by IQVIA has …
Fujifilm flu drug effective in treating coronavirus in Chinese clinical trials
March 18, 2020Research and Development COVID-19, Wuhan Coronavirus, coronavirus
A flu drug has appeared to be effective in treating COVID-19, according to recent clinical trials in China. The drug, …
100 coronavirus cases linked to Biogen-hosted event in Boston, State of Massachusetts confirms
March 18, 2020Manufacturing and Production, Medical Communications, Research and Development Biogen, coronavirus, pharma
It is now known that around 100 of the known cases of the COVID-19 coronavirus can be traced to an …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
March 18, 2020Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, merger, pharma
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles on the road to regulatory …
NICE promotes Professor Gillian Leng as its new Chief Executive
March 18, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, pharma
NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng …
New technologies and industry collaboration will help fight chronic illnesses
March 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma
Authored by Dan Boot, Head of Digital Innovation at RB Health.Around the world, populations are aging. According to the World …
European Commission offers €80m to CureVac to develop coronavirus vaccine
March 17, 2020Manufacturing and Production, Research and Development, Sales and Marketing CureVac, EU, US, coronavirus
Following confirmation of reports that US President Donald Trump sought to persuade a biotech to provide US-exclusivity for a potential …
Novo Nordisk halts three haemophilia studies after participants suffer thrombotic events
March 17, 2020Manufacturing and Production, Research and Development Novo Nordisk, haemophilia, pharma
Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one of its Phase 2 clinical …
Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer
March 17, 2020Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma
AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
